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An acute intravenous administration of loo&kg body weight of recombinant tumour necrosis factor-a (TNF) resulted in a time-dependent increase 
in the levels of both free and conjugated ubiquitin m rat skeletal muscle. The effects of the cytokine were more pronounced in the red muscle soleus 
than in the white muscle EDL. In the former muscle type. TNF-treatment also resulted in a time-dependent increase in the percentage of free 
ubiquitin. The results suggest that the ubiquitm system for non-lysosomal protein degradation could have a very important role in the mechanism 
triggered by TNF which is responsible for enhanced muscle proteolysis in sepsis and other pathological states. 
TNF: Protein metabolism; Ubiquitm; Cachexla 
1. INTRODUCTION 
Cachexia is a poorly understood syndrome character- 
ized by anorexia, weight loss, profound metabolic ab- 
normalities and progressive host wasting which may 
result in death [l-3]. Tissue wasting involves mainly 
adipose tissue and skeletal muscle. Numerous reports 
attribute the cachectic state of the host to cytokines 
releases as a result of invasive stimuli (see Evans et al. 
[4] for review). However, while the role of cytokines, 
particularly tumour necrosis factor-a (TNF), on adi- 
pose tissue dissolution seems to be clear [5-71, the effects 
of the cytokine on muscle metabolism lead to more 
confusing results (see ArgilCs et al. [8] for review). 
tein breakdown. Recently, Goodman [ 131, measuring 
both tyrosine and 3-methylhistidine release by incu- 
bated rat muscles of animals acutely treated with the 
cytokine, concluded that TNF was involved in activat- 
ing muscle proteolysis. 
Muscle wasting is generally accepted to be caused by 
an increase in protein breakdown. Chronic treatment of 
rats with recombinant TNF resulted in depletion of 
body protein compared with pair-fed control animals 
[9]. Indeed, chronic treatment with either recombinant 
TNF or interleukin- 1 -p (IL- 1) resulted in a body protein 
redistribution and a significant decrease in muscle pro- 
tein content associated with coordinate decreases in 
muscle mRNA levels for myofibrillar proteins [lo]. 
Studies involving administration of recombinant TNF 
in vivo have shown an increase in nitrogen efflux from 
skeletal muscle of non-weight losing humans with dis- 
seminated cancer [l 11. Flores et al. [12], by infusing 
[‘4C]leucine to rats, showed that chronic recombinant 
TNF administration significantly enhanced muscle pro- 
The precise mechanism by which intracellular pro- 
teins are degraded is largely unknown, although it is 
accepted that proteolysis can occur both within and 
outside of lysosomes. In particular, lysosomic pro- 
teinases, mainly cathepsins. do not seem to be involved 
in the degradation of myofibrillar proteins in rat skele- 
tal muscle [14]. Ubiquitin, a 8,600-Da peptide, is in- 
volved in the targeting of proteins undergoing cytosolic 
ATP-dependent proteolysis. In the cell, ubiquitin can be 
found free or conjugated in an isopeptide linkage to 
other cellular proteins. Proteins with multiple ubiquitins 
are the ones targeted for degradation by an ATP-de- 
pendent protease [15-l 81. The ubiquitin system is postu- 
lated to account for the turnover of ‘short-lived’ normal 
proteins [19] and abnormal proteins formed during 
stress such as heat-shock [20]. The role of ubiquitin- 
dependent proteolysis can be tested by exploiting the 
ubiquitin moiety as an immunological probe [21,22] of 
substrate specificity. Bearing this in mind, the objective 
of the present study was to evaluate the possible role of 
the ubiquitin-mediated sytem in TNF-induced proteoly- 
sis in rat skeletal muscle. It has been studied by Western 
blot analysis of both free and conjugated ubiquitin in 
muscle tissue of TNF-treated animals. 
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2. MATERIALS AND METHODS 
2.1. Animals 
Female Sprague-Dawley rats (160-l 80 g) from our colony (Faculty 
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of Medicine. Umversity of Barcelona) were used. The animals were 
housed m individual polypropylene cages, maintained at 22-23°C 
(with a 12 h-light/l2 h-dark cycle). They were fed Purma laboratory 
chow ad hbitum. 
2.2. Blochemcals 
All enzymes and coenzymes were either obtained from Boehringer 
Mannhelm. (Barcelona. Spam) or from Sigma (St. Louis, USA). Re- 
combinant-derived TNF was generously given by BASF/Knoll 
(Ludwigshafen, Germany). Polyclonal rabbit anti-rat-ubiqmtm was 
provided by Dr. Arthur L Haas. Department of Biochemistry, Med- 
ical College of Wisconsin, Milwaukee (Wlsconsm, USA). 
2.3. TNF twutment 
Two different treatments were used. In the chronic study, TNF was 
given intraperitoneally for 8 days at a dose of 100puglkg (twice a day. 
at 08.00 and 20.00 h). Control animals received 0.5 ml of vehicle 
(Krebs-Henseleit saline). In the acute study, a single dose of TNF (100 
&kg) was adtnmistered intravenously through one of the tail veins 
under light dlethylether anaesthesia. Control animals received 0.5 ml 
of vehicle (same as above). All injections were admimstered between 
8.00 and 9.00 h. with the animals bemg killed either 1, 3, or 8 h later. 
Food was available during this period. 
2.4. Isolation undpreparatton of muscle tlssw for quant?fication offree 
and conjugated ubiqultin 
The red soleus and white extensor dlgitorum longus (EDL) were 
removed under penthobarbital anaesthesia Excised muscles were 
quickly weighed and rapidly frozen in liquid N2. Ubiquitin pools in 
muscle extracts were determmed by immunochemical analysis. Indl- 
vldual muscles were finely homogenized using a Polytron homogemzer 
in 2 ml of Ice-cold SO mM Tris-HCl buffer contaimng 0.25 mM su- 
crose, 5 mM EDTA. 1% (w/v) sodium dodecyl sulphate. 0.1 trypsm 
inhibitor U/ml aprotmm, 1 PM leupeptin, 1 PM pepstatm. 5 mM 
N-ethylmaleimide and 1 mM PMSF pH 7 4. The resulting homoge- 
nates were centrifuged at 4°C for 20 min at 15.000 x g to remove cell 
debris. Ahquots of the supernatants were stored at -80°C. Protein 
content was measured usmg the Bradford assay [23] using bovme 
serum albumin as a standard. 
2.5. Western blots 
Aliquots of the supernatants were diluted with 0.5 volumes of 30 
mM phosphate buffer pH 7.0 contaming 7.5% (w/v) sodmm dodecyl 
suiphate and 0.15% (w/v) dithlotreitol, 0.05% (w/v) Bromophenol blue 
and 30% glycerol. Samples were bolled for 5 mm, SO pg of protein 
samples being assayed for ubiquitin conjugates. Sodmm dodecyl 
sulphate (SDS)-15% polyacrylamide gel electrophoresls was per- 
formed on muscle samples. Proteins were transferred to Immobilin in 
25 mM Tris buffer contaming 144 mM glycine, 25% methanol, 0.02% 
SDS for 4 h. The filter was blocked for 1 h at room temperature in 
buffer A (25 mM Tns-HCI pH 7.5, 150 mM NaCI, 25 mg/ml BSA and 
0.02% sodium azide) and incubated for 90 mm with an ant]-ubiqmtm 
polyclonal antibody which recognized free and conjugated ubiqmtm 
at a concentration of 10 @ml in buffer A. Detection of antibody- 
antigen complexes was carried out using [“‘Ilprotein A according to 
standard procedures. Quantitation of the different autoradlographs 
was done by densitometry using a scanning mlcrodensitometer. Data 
for both free and conjugated ubiqultin were normalized to extract 
protein concentration determined by the Bradford assay [23]. Statisti- 
cal comparisons between groups were carried out by means of the 
Student’s t-test. 
3. RESULTS AND DISCUSSION 
Increased muscle catabolism is an important compo- 
nent of the metabolic response to acute and chronic 
inflammatory processes accompanying infections [24], 
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trauma [25]. tissue injury [26] and cancer cachexia [27]. 
Although the protein synthesis mechanisms are well 
known, those involved in protein degradation remain 
somewhat obscure. Protein degradation takes place by 
two major pathways. The lysosomal pathway is of poor 
selectivity and seems to be responsible for basal degra- 
dation of long-life proteins in normal dietary conditions 
and also for enhanced degradation in pathological 
states [28]. The cytosolic pathway is ATP-dependent 
and shows high specificity for short-life proteins [29]. In 
this second degradative pathway, the protein ubiquitin 
seems to be involved in targeting those proteins under- 
going ATP-dependent degradation by the formation of 
ubiquitin conjugates with ulterior regeneration of free, 
functional ubiquitin. Since cells contain a substantial 
pool of proteolytically stable conjugates, ubiquitin 
binding cannot indicate absolute commitment to degra- 
dation; however, the proteolytic rate seems to be de- 
pendent on the formation of the conjugates [30]. It was 
the objective of this study to prove if the ubiquitin sys- 
tem for protein degradation was involved as a possible 
mechanism for the proposed action of TNF on muscle 
proteolysis. In order to test this hypothesis. the animals 
received repetitive cytokine administrations. 
3.1. Chronic TNF administration 
Chronic administration of 100 ,ug of recombinant- 
derived TNF resulted in a significant decrease in per- 
centual body weight increase at day 1; however, succes- 
sive cytokine administrations produced no changes in 
food intake or body weight for the rest of the period 
studied (results not shown). This is in agreement with 
other studies where repetitive TNF administrations 
have failed to promote changes in body mass deposi- 
tion, Stovroff et al. [31] saw that repetitive administra- 
tion of recombinant TNF to rats resulted only in a 
transient weight loss followed by rapid recovery 24 h 
after the initiation of the treatment. It is possible that 
the tolerance developed in all these studies may be due 
to the formation of antibodies against TNF. specially 
if species-specific TNF is not used. However, it has been 
demonstrated that when human recombinant TNF was 
injected into rats. antibody formation did not begin 
until the tenth day of injection. Another factor to be 
taken into consideration is that episodic administration 
of TNF may not be a physiologically sound test of the 
normal function of the cytokine. In this way, only when 
TNF was administered using osmotic minipumps [32], 
a significant reduction of body weight has been re- 
ported. Alternatively, Oliff et al. [33] after cloning the 
human TNF gene into a mammalian expression vector 
under the control of a constitutive promoter, and trans- 
fecting it into a tumorogenic cell line. were able to dem- 
onstrate progressive weight loss after transplantation of 
the tumour cells into nude mice. 
TNF treatment did not result either in changes in 
liver or gastrointestinal tract weights (results not 
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Fig. 1. Western blots of muscle (soleus and EDL) extracts from rats 
following a single dose of recombinant TNF (100 &kg) admimstra- 
tion. 50 pg of protein was loaded m all wells. Ubiqmtm conjugates of 
different molecular weights are shown. UB = free ubtquitin. 
shown). Although there was a tendensy for soleus mus- 
cles to be smaller in the TNF-treated (46 & 2 mg/lOO g 
b.w.) than in control animals (52 + 2 mg/lOO g b.w.), it 
did not reach statistical significance. EDL muscle 
weight was also unchanged following TNF treatment 
(49 + 2 mg/lOO g b.w. (control) and 49 & 2 mg/lOO g 
b.w. (TNF-treated)). Total and specific protein content 
of both soleus and EDL muscles was not affected by 
TNF treatment (results not shown). As would be ex- 
pected, no changes in either free or conjugated ubiquitin 
were seen either in soleus or EDL muscles (Table I). As 
commented above, repeated administration of cytoki- 
nes, TNF in particular, may not be a physiologically 
sound test of the actions of these compounds. This is 
related to the fact that TNF has a very short life once 
in the circulation [34] and also to the fact that animals 
become tolerant after episodic administrations. Bearing 
this in mind, we decided to carry out acute administra- 
Table I 
Free and conjugated ubiquttin after chronic TNF admmistration 
Type of 
muscle 
Fraction Treatment 
Control TNF 
Soleus FUB 0.130 2 0.037 0.117 f 0.021 
(4) (4) 
CUB 1.380 f 0.266 1.750 f 0.034 
(5) (5) 
EDL FUB 0.223 + 0.071 0.172 ? 0.014 
(4) (5) 
CUB 5.622 + 0.582 4.582 f 0.645 
(4) (5) 
For further details, see section 2. All data are expressed in arbitrary 
units/50pg of protein and represent the mean * S.E.M. with the num- 
ber of different animals indicated in parentheses. FUB = free ubtq- 
uitm, CUB = conjugated ubiquitin. 
tions to see if the cytokine could activate ubiquitin syn- 
thesis and conjugation before any tolerance had devel- 
oped in the animal. 
3.2. Acute TNF administration 
The results presented in Table II show an increased 
presence of both free and conjugated ubiquitin in soleus 
muscles of TNF-treated rats. The increase is significant 
both at 3 and 8 h after the administration of the cytok- 
ine thus indicating relatively long-term effects. Con- 
cerning EDL muscles, a significant rise in free ubiquitin 
can also be observed 3 h after the administration of the 
cytokine, the conjugated ubiquitin fraction being ele- 
vated still 8 h after administration (Table II, Fig. 1). The 
greater increases in both free (4.2-fold) and conjugated 
(2.1-fold) ubiquitin are observed in soleus muscles, 
while EDL ones show a more moderate increase for 
both free (1.5-fold) and conjugated (1.3-fold) ubiquitin, 
8 h after the administration of the cytokine (Table II, 
Fig. 1). Different studies suggest that red muscles have 
a higher rate of total protein turnover than white mus- 
cles [35]. This observation is consistent with our results 
indicating that soleus muscles are affected to a larger 
extent in the increase in total ubiquitin than EDL ones 
(Table II). 
3.3. Concluding remarks 
Although several studies have clearly demonstrated 
the involvement of TNF either in inducing muscle pro- 
teolysis [12-l 3,361 or reducing amino acid uptake [37], 
the identification of the actual mechanisms taking place 
in skeletal muscle has received little attention. While 
Hall-Angeras et al. [24] have demonstrated that both 
myofibrillar proteinase and cathepsin B activities are 
increased in skeletal muscle of septic rats, this effect 
being mediated by TNF [36], concomitant with stimu- 
lated total and myofibrillar protein breakdown, others 
have demonstrated that lysosomes are not involved in 
the degradation of myofibrillar proteins in rat skeletal 
Table II 
Free and conjugated ubiquitin after an acute TNF admimstration 
Hours after 
TNF 
Type of muscle 
Soleus EDL 
FUB CUB FUB CUB 
1 1.81 & 0.34 1.48 f 0.28 1.30 + 0.13 0.97 f 0.08 
3 4.87 f 0.67** 2.14 + 0.13** 1.63 + 0.09** 1.14 + 0.05 
8 4.23 + 0.53** 2.12 + 0.12** 1.46 f 0.18 1.28 f 0.06* 
For further details, see section 2. All data are expressed as arbitrary 
units/50 pg of protein divided by the values of time 0 h. The values 
represent the mean 2 S.E.M. for four different animals. FUB = free 
ubiquttin. CUB = conjugated ubiquttin. Statistical comparisons be- 
tween control and TNF groups were carried out using the Student’s 
t-test. *P < 0.05, **P < 0.01. 
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muscle. The present study thus clearly contributes to the 
elucidation of the mechanism by which TNF stimulates 
muscles protein breakdown, the ubiquitin system being 
involved. Whether the cytokine is capable of activating 
the ubiquitinization of muscle proteins directly (the 
presence of TNF receptors in most tissues has been 
reported [38]), or indirectly (via glucocorticoids or other 
hormonal changes) remains to be investigated and will, 
no doubt, provide work for future promising investiga- 
tions. 
Acknowledgements~ This work was supported by grants from the 
Fondo de Investigaciones Sanitarias de la Seguridad social (F.I.S.) 
(90/663) of the Spamsh Health Ministry and from the DGYCT (PB 
90-0497) of the Spanish Mmistry of Education and Science. C.G M. 
and M.L. are recipients of pre-doctoral scholarships from the F.I.S. 
and the Generalitat de Catahmya, respectively. We are very grateful 
to BASF/Knoll (Ludwigshafen, Germany) for the generous supply of 
recombinant derived TNF and to Dr. Arthur L. Haas. Department 
of Biochemistry. Medical College of Wisconsm. Milwaukee, Wiscon- 
sm, U.S.A. for the generous supply of anti-rat-ubiquitin. 
REFERENCES 
111 
PI 
131 
141 
[51 
PI 
[71 
PI 
[91 
UOI 
1111 
UT 
Lawson, D.H.. Richmond, A.. Nixon, D W. and Rudman, D. 
(1982) Annu. Rev Nutr 2. 227-301. 
Strain. A.J (1979) Invest. Cell Path01 2. 181-193. 
Theologides, A. (1979) Cancer 43, 20042012. 
Evans, R.D., Argiles. J.M. and Williamson, D.H. (1989) Chn. 
Sci. 77. 3577364. 
Price, J.R., Ohvecrona, T. and Pekala. P.H. (1986) Arch. Bio- 
them. Biophys. 251, 7388746. 
Semb. H.. Peterson, J., Tavernier, J. and Ohvecrona. T. (1987) 
J. Biol. Chem. 262, 8390-8394. 
Evans, R.D. and Williamson, D.H. (1988) Biochem. J. 256,1055- 
1058. 
Argiles, J.M., Garcia-Martinez, C.. Llovera, M. and Lopez-Sori- 
ano. F.J. (1992) Med. Res. Rev. 12. 637-652. 
Tracey. K.L , Wei. H.. Manogue. K.R., Fong. Y., Hesse. D.G., 
Nguyen, H.T., Kuo, G.C.. Beutler, B.. Cotran. RS . Ceramt. A. 
and Lowry, SF. (1988) J. Exp. Med. 167. 1211-1227. 
Fong, Y., Moldawer, L.L.. Morano, M., Wei. H.. Barber. A., 
Manogue. K., Tracey, K.J., Kuo, G.. Ftschman, D.A., Ceramt. 
A. and Lowry, SF. (1989) Am. J. Physiol. 256. R659-665 
Warren, R.S . Stames. H.F Jr., Gabrilove, J L.. Oettgen, H.F 
and Brennan, M.F. (1987) Arch Surg. 122, 1396-1400. 
Flores. E.A.. Bistrtan, B.R., Pomposelli, J.J., Dmarello. C.A.. 
Blackburn, G.L. and Istfan, N.W (1989) J. Clin. Invest. 83, 
16141622. 
u31 
1141 
u51 
[I61 
u71 
P81 
1191 
PO1 
PII 
WI 
1231 
~241 
P51 
WI 
~271 
PI 
~291 
1301 
1311 
[321 
Goodman, M.N. (1989) Am. J. Phystol. 260, 19-24. 
Lowell, B.B., Ruderman, N.B. and Goodman, M.N. (1986) Bio- 
them. J. 234, 2377240. 
Finley, D. and Varshavsky. A. (1985) Trends Btochem. Set. IO. 
343-347. 
Rechsteiner, M. (1991) Cell 66, 615-618. 
Ciechanover. A., Fmley. D. and Varshavsky. A. (1984) J. Cell. 
Biochem. 24. 27-53. 
Hershko, A., Ciechanover. A., Heller. H., Haas, A.L. and Rose, 
LA. (1980) Proc. Nat]. Acad. Sci. USA 77, 178331786. 
Ciechanover. A., Finley, D. and Varshavsky, A. (1984) Cell 37, 
57-66. 
Bond. U., Agell, N.. Haas, A.L.. Redman, K. and Schlesinger, 
M.J. (1988) J. Biol. Chem. 263, 23842388. 
Haas. A.L. and Bright, P.M. (1985) J. Biol. Chem. 260. 12464 
12473. 
Riley. D.A.. Bain. J.L.W , Elhs, S. and Haas. A.L. (1988) J. 
Histochem. Cytochem. 36, 521-632. 
Bradford. M N. (1976) Anal. Biochem. 72. 2488254. 
Hall-Angeras, M.. Hasselgren. P.O., Dimhch, R.V.W and 
Fisher, J.E. (1991) Metabolism 40, 3022306. 
Long. C.L . Birkhahn, R.H.. Geiger, J.W.. Betts, J E and 
Schiller, W R. (198 1) Metabohsm 30, 7655776. 
Odessey. R. and Parr, B. (1982) Metabolism 31, 82287. 
Tessitore, L.. Bonelli. G. and Baccino. F.M. (1987) Biochem. J. 
241, 153-159. 
Knowles. S.E. and Ballard, F.J. (1976) Biochem. J. 156.609-617. 
Goldberg, A.L. and St. John, A.C. (1976) Annu. Rev. Biochem. 
45. 7477803. 
Haas, A.L. and Riley. D.A. (1988) in: The Ubiqumn System 
(Schlesmger. M. and Hershko, A., Eds.) Cold Spring Harbor 
Laboratory, Cold Spring Harbor. New York. 
Stovroff, M C., Fraker, D.L.. Swedenborg. J.A. and Norton, J.A. 
(1988) Cancer Res 48, 45674572. 
Darling. G., Fraker. D.L.. Jensen, J.C.. Gorschboth. C.M and 
Norton. J.A. (1990) Cancer Res. 50, 40084013. 
[33] Oliff, A., Defeo-Jones. D., Bayer. M., Martinez. D.. Kiefer, D., 
Vuocolo, G., Wolfe, A. and Socher, S.H. (1987) Cell 50.5555563. 
[34] Beutler, B and Cerami, A. (1988) Annu. Rev. Btochem. 57. 
505-518. 
[35] Li, J.B. and Goldberg, A.L. (1976) Am. J. Physiol. 231.441448. 
[36] Zamir, O., Hasselgren, P.O.. Kunkel. S.1 , Frederick. J.. HI- 
gashiguchi. T. and Fisher. J.E. (1992) Arch. Surg. 127. 1760.. 
1774. 
[37] Argiles. J.M.. Lopez-Soriano, F.J.. Wiggins. D and Williamson. 
D.H. (1989) Biochem. J. 261. 355-362. 
[38] Aggarwal, B.B.. Eessalu, T.E. and Harr. P.E. (1985) Nature 318. 
6655667. 
214 
